Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-01-05 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return detailing movements in securities, specifically authorized and issued shares, share options, and other related share capital information for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules. The content focuses on share capital movements and confirmations related to securities listed on the SEHK. There are no financial statements, earnings data, or management discussion. The document is a regulatory submission reporting share capital movements rather than a financial report or announcement of voting results. This type of document fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-01-05 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities for an equity issuer listed on the Hong Kong Stock Exchange. It includes information on authorized and issued share capital, share options, confirmations by the company secretary, and compliance with listing rules. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting on share capital and share movements for the month ended 31 December 2022. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital movements and confirmations related to securities issuance under exchange rules. Therefore, it fits best under Regulatory Filings (RNS).
2023-01-03 English
ANNOUNCEMENT - LEGAL PROCEEDINGS INVOLVING THE GROUP
Legal Proceedings Report Classification · 100% confidence The document is an announcement from Ascletis Pharma Inc. regarding legal proceedings involving the company. It references complaints filed by Viking Therapeutics with the United States International Trade Commission and a U.S. District Court. The document is titled 'ANNOUNCEMENT LEGAL PROCEEDINGS INVOLVING THE GROUP' and discusses the nature of the complaints and the company's response. There are no financial statements, no detailed financial data, or report attachments. The document is clearly an update on legal matters, fitting the category of Legal Proceedings Report. The document length is 3284 characters, which is not extremely short, and it contains substantive information about the legal complaints. Therefore, the appropriate classification is Legal Proceedings Report (LTR).
2023-01-02 English
GRANT OF SHARE OPTIONS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the grant of share options by Ascletis Pharma Inc. It details the number of options granted, the exercise price, the grant date, and the validity period. It is made pursuant to a listing rule and is a formal disclosure of a share option grant. The document is relatively short (2739 characters) and does not contain financial statements or detailed financial analysis. It is not a report but an announcement of a capital-related event (grant of share options). This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share option grants.
2022-12-30 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES NOTICE OF ISSUANCE OF THE U.S. PATENT FOR ORAL VIRAL INHIBITOR ASC10 AND ITS DERIVATIVES
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the issuance of a U.S. patent for their oral viral inhibitor ASC10 and its derivatives. It includes details about the patent number, issue date, and the significance of the patent to the company. The document is relatively short (3412 characters) and serves as a public announcement of a business development rather than a financial report or regulatory filing. There is no financial data, no mention of shareholder votes, no management changes, no earnings information, or other report types. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category that covers miscellaneous company news that does not fit other specific categories.
2022-12-19 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE PHASE I CLINICAL RESULTS OF ORAL RDRP INHIBITOR ASC10 FOR COVID-19
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding positive Phase I clinical trial results for a drug candidate ASC10. It contains detailed clinical data and safety information but does not present comprehensive financial statements or annual/interim report data. It is not a regulatory filing, certification, or a report publication announcement. The content focuses on business development and clinical trial progress, which aligns with a Capital/Financing Update or general business update. However, since it is about clinical trial results and drug development progress rather than fundraising or capital structure changes, the best fit is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2022-12-12 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.